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Abstract
Background: Breast cancer is the second most frequent type of cancer affecting women. We are increasingly aware that
changes in mRNA splicing are associated with various characteristics of cancer. The most deadly aspect of cancer is
metastasis, the process by which cancer spreads from the primary tumor to distant organs. However, little is known
specifically about the involvement of alternative splicing in the formation of macroscopic metastases. Our study investigates
transcript isoform changes that characterize tumors of different abilities to form growing metastases.
Methods and Findings: To identify alternative splicing events (ASEs) that are associated with the fully metastatic phenotype
in breast cancer, we used Affymetrix Exon Microarrays to profile mRNA isoform variations genome-wide in weakly
metastatic (168FARN and 4T07) and highly metastatic (4T1) mammary carcinomas. Statistical analysis identified significant
expression changes in 7606 out of 155,994 (4%) exons and in 1725 out of 189,460 (1%) intronic regions, which affect 2623
out of 16,654 (16%) genes. These changes correspond to putative alternative isoforms—several of which are novel—that
are differentially expressed between tumors of varying metastatic phenotypes. Gene pathway analysis showed that 1224 of
genes expressing alternative isoforms were involved in cell growth, cell interactions, cell proliferation, cell migration and cell
death and have been previously linked to cancers and genetic disorders. We chose ten predicted splice variants for RT-PCR
validation, eight of which were successfully confirmed (MED24, MFI2, SRRT, CD44, CLK1 and HNRNPH1). These include three
novel intron retentions in CD44, a gene in which isoform variations have been previously associated with the metastasis of
several cancers.
Conclusion: Our findings reveal that various genes are differently spliced and/or expressed in association with the
metastatic phenotype of tumor cells. Identification of metastasis-specific isoforms may contribute to the development of
improved breast cancer stage identification and targeted therapies.
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Introduction
In breast cancer patients, tumor metastases at distant sites are
the main cause of death [1]. However, the molecular mechanisms
of metastasis of breast cancer remain unclear. It is thought that
changes occurring at the level of RNA processing contribute to
cancer. Alternative splicing (AS) of pre-mRNA, a key post-
transcriptional mechanism allowing for the production of distinct
proteins from a single gene, affects over 90% of human genes
[2,3]. Such splicing events are responsible for generating mRNAs
that encode protein isoforms that can have very different biological
properties and functions. A well-studied example is the BCL-X
gene, whose two major transcript isoforms produce two proteins
having antagonistic functions [4]: the short form (BCL-XS)
promotes apoptosis while the long form (BCL-XL) is anti-
apoptotic. Moreover, overexpression of BCL-XL has been
reported to enhance the metastatic potential of breast tumor cells
in patients [5]. Another interesting example is CD44, a multi-
functional cell adhesion protein for which many splice variants
have been associated with the growth and progression of multiple
tumor types [6,7,8]. CD44 shows an unusual pattern of splice
variants in mammary tumorigenesis, which arises from the
differential usage of 10 internal exons. In breast cancer metastases,
CD44 isoforms with variable inclusion of these 10 exons are
expressed; whereas preneoplasias show a more restricted exon
inclusion pattern [9]. The CD44v5 isoform has been identified to
enhance tumor cell invasiveness [10], and tumor cells expressing
the CD44v4-10 variant form larger volume primary tumors and
more metastases compared to tumors expressing wild-type CD44
[11]. Moreover, changes in splicing during cancer appear to alter
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processes which are hallmarks of metastasis [12]. Cancer
metastasis is a progressive process and thus transcript isoforms
associated with specific metastatic phenotype may serve as
potential biomarkers for aggressive disease and may be relevant
in the development of targeted treatment strategies of breast
cancer patients.
The Affymetrix GeneChip Exon 1.0 ST (Exon Array), a tool for
exon-based transcriptome profiling, can be used to detect
differences in isoform-level expression and has been applied
successfully in several studies [13,14,15]. It allows the expression
profiling of over a million individual exons, both those that are
known and predicted. In this study, we used this technology in a
murine breast cancer model to identify changes in splicing that are
associated to metastatic phenotypes. We simultaneously analyzed
exon and transcript expression in tumor tissues derived from three
murine mammary carcinoma cell lines (168FARN, 4T07 and
4T1), each possessing different metastatic phenotypes [16]. The
criterion used to assign the metastatic potential of these cell lines is
based on their ability to form lung metastases. 168FARN tumor
cells can be detected in lymph nodes but fail to extravasate and are
rarely detected in the lungs. Cells from 4T07 tumors reach the
lung via the blood, but are unable to develop into macroscopic
metastatic nodules. Lastly, 4T1 cells possess the ability to
spontaneously metastasize to distant sites, including the lung,
bone and liver [17]. By performing statistical analysis of the Exon
Array data, transcript isoforms associated with metastatic
phenotypes of these different tumors were identified. Nearly
16% of genes display at least one differently expressed exon across
the panel of murine breast tumors. Additionally, gene pathway
profiling was performed with candidate genes using the Ingenuity
Pathway Analysis software. Half of these genes are known to be
associated with cancer hallmarks and genetic disorders, while the
remaining candidates have no established link with cancer
progression and metastasis and may constitute novel candidates
for metastasis diagnosis and therapy.
Results
To seek transcriptome changes at the exon scale during
metastasis progression, we measured global exon expression in
murine breast tumors that have differential metastatic behaviors.
The breast carcinoma cell lines were individually injected into the
mouse mammary fat pads as previously described [18] and total
RNA was purified from the resulting tumors once they reached a
volume between 100 and 125 mm
3. Samples were then labeled
and hybridized to GeneChip Mouse 1.0 ST arrays that provide
multiple probes (probe sets) per exon and target over a million
known and predicted exons. The microarray data has been
deposited in the Gene Expression Omnibus Database (accession:
GSE21994). We analyzed the full probe set annotation (493,710
probe sets), interrogating 345,454 exons and introns. In addition to
the core probe sets, we extended our analysis to the non-core
probe sets, which are those supported by EST and predictive
evidence not present within RefSeq and full-length mRNA
GenBank records. Concurrent with exome profiling, we estimated
the gene-level intensity by summarizing, for each gene, the signal
values of all the probe sets belonging to the gene (meta-probe set).
Hence, the full dataset was summarized into 16,654 unique well-
annotated transcripts. We applied several filtering steps to discard
genes and exons with expression values close to background in an
effort to minimize the false positive rate (see Methods). We
obtained 183,610 expressed probe sets, corresponding to 137,950
exons or introns belonging to 11,082 genes. To determine
differently expressed exons and genes across tumor samples, we
simultaneously performed either a one-way ANOVA test on probe
set logarithmic intensities or a one-way ANOVA test on meta-
probe set logarithmic intensities. At the probe set level, we
performed two concurrent analyses: a probe set expression-
intensity analysis and a probe set gene-level normalized intensity
analysis. The gene-level normalized intensity is the ratio of the
probe set expression intensity to the expression intensity of the
meta-probe set that the probe set belongs to. The splicing index
(SI) for a probe set is then defined as the ratio of gene-level
normalized intensities in one sample relative to another.
Subsequent to ANOVA tests, we applied a 0.05-level FDR (False
discovery rate) correction to determine the P-value threshold to
identify significant exons (P,6.36610
24 for the probe set
expression analysis; P,7.10610
24 for the SI analysis) and the
significance of whole gene expression (P,8.46610
23: over-
expressed in a sample). Differentially expressed exons between
paired samples were located by performing pairwise T-test
comparisons (168FARN and 4T07 against 4T1). The log2
transformed expression fold-changes (4T07/4T1 and
168FARN/4T1) between paired sample comparisons were also
computed.
Gene expression and isoform variations specific to tumor
metastatic phenotype
We obtained 10,744 probe sets targeting 9331 (2.7%) introns or
exons showing significant expression changes belonging to 2623
(15.7%) genes. Of these, 1772 (10.6%) genes displayed expression
changes at the whole transcript level while 851 (5.1%) showed
isoform changes without corresponding whole gene expression
changes. To visualize ASEs in the context of EST/mRNA or
genome annotation, we uploaded our data as a track in the UCSC
Genome Browser [19]. For each gene, we plotted the paired T-test
P-values and the expression fold-changes of each individual exon
(examples shown in Figure 1). Using this visualization, we
manually curated the results and selected 203 genes (143 from
the expression intensities analysis and 60 from the SI analysis;
Details reported in Supplementary File S1 and Supplementary File
S2) for which the transcript variation pattern was clearly
interpretable and confidently classifiable into the gene expression
change category or into the standard ASE categories. These 203
candidates showed evidence for differential promoter usage,
polyadenylation site usage, ASE and whole gene expression
changes. We calculated the proportion of each isoform variation
type among our classified candidate genes, which revealed that
26.1% of these genes showed whole gene expression changes with
some of them showing additional splicing changes. A large
proportion of genes showed only isoform changes (examples in
Table 1), namely intron inclusion or inclusion of cryptic,
unannotated exons (46.4%) and cassette exon usage (13.5%).
Furthermore, 7.2% of isoform changes occurred at the level of
transcript initiation or transcript termination. Thirteen genes
showed changes within the UTR regions: three genes had
differential 59 UTR changes and 10 presented 39 UTR changes.
We found only one gene showing an alternative 59 splice site.
However, the remaining significant genes (2420) presented
complex variation patterns that were difficult to categorize. Below,
we describe some potentially interesting examples detected by the
analysis.
The process of pre-mRNA splicing is regulated by a large
number of ‘‘splicing-factors’’ and the misregulation of such genes
may be particularly detrimental to many downstream splicing
events. HNRNPH1 and CLK1, two trans-acting splicing regulator
factors, are predicted by our computational analysis to be
Splicing in BC Metastasis
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member of the hnRNP family and retains an intronic sequence
between exons 9 and 10 in 168FARN and 4T07 mammary tumors
compared to 4T1 tumors. This splice-form causes a reading
frameshift and a protein truncation. The hnRNP proteins are
required for pre-mRNA processing and maturation and bind to
newly synthesized RNA in the nucleus until they are exported to
the cytoplasm. Interestingly, a frameshift mutation in HNRNPH1
has been previously identified in gastric cancer [20]. The second
example, CLK1, shows a retained intronic sequence in 4T1-
derived mammary tumors, situated between exons 5 and 6. This
intron retention leads to a reading frameshift and the disruption of
a kinase domain in the protein product. This gene codes for a
member of the CDC2-like family. Expressed in the nucleus, this
protein phosphorylates other serine/arginine-rich (SR) proteins,
which has been show to be involved in the regulation of splice site
selection during pre-mRNA maturation [21].
We also found isoform variants of several genes involved in cell
growth, cell movement, cell proliferation and apoptosis, including
CD44, PHB and MAPK14. CD44 isoform variations in cancer
have been associated with the metastatic ability of tumor cells,
being involved in numerous processes, including cell proliferation,
adhesion and invasion [22]. This protein increases the adhesion
and invasion of breast cancer cells [7,23] and decreases cell death
and apoptosis of colon cancer cells [24]. We identified a novel
isoform of CD44 showing retention of intronic sequences with no
previous RefSeq or full cDNA evidence in publicly-available
sequence databases (Figure 1C). In this variant, two introns – one
between between exons 5 and 6 and the other between exons 9
and 10 were retained in 4T1-derived fully metastatic mammary
tumors. These result in reading frame-shifts in the transcript. We
also noted a high inclusion rate of exons 8, 11 and 13 within CD44
from 4T1-derived tumors compared to 168FARN and 4T07-
derived tumors.
Another example includes PHB-exon 4, which was found to be
predominantly expressed in 4T1-derived mammary tumors
compared to those arising from the injection of 168FARN or
4T07 cells. The lack of PHB-exon 4 caused a reading frameshift
and the removal of 26% of SPFH, an integral membrane domain.
Prohibitin (PHB) is an evolutionary conserved gene that is highly
Figure 1. Examples of visualization of gene expression patterns showing isoform variations. A: Visualization of the expression pattern of
MED24 gene showing an alternative start in 4T1. In the top panel, the horizontal scale corresponds to each probe set within the gene from the 59 to
39 ends. The blue bars indicate the comparison between 168FARN and 4T1 samples. From top to bottom we plotted the log2(fold-change) in
expression, between the samples compared, and the statistical significance, 2log10(p-value). The bottom panel shows the log10(expression intensity)
of individual probe sets (from the top panel) in samples 168FARN and 4T1. Note that the seven last probe sets and the 39 UTR region that are over-
expressed only in 4T1 indicate an additional isoform in 4T1 starting from exon 20 start. B: Visualization of the expression pattern of SRRT gene
showing an intron inclusion. In the top panel, the horizontal scale corresponds to each probe set within the gene from the 59 to 39 ends. The blue
bars indicate the comparison between 168FARN and 4T1 samples. From top to bottom we plotted the the log2(fold-change) in gene-level normalized
intensity between the samples compared and the statistical significance, 2log10(p-value). The bottom panel shows the log10(gene-level normalized
intensity) of individual probe sets (from the top panel) in samples 168FARN and 4T1. We note an intron inclusion between exons 5 and 6 in samples
168FARN. C: Visualization of the expression pattern of CD44 gene showing several internal cassette exons and three novel intron inclusions. In the top
panel, the horizontal scale corresponds to each probe set within the gene from the 59 to 39 ends. The blue bars indicate the comparison between
4T07 and 4T1. From top to bottom we plotted the log2(fold-change) in expression, between the samples compared. The bottom panel shows a close-
up of the CD44 region containing the differentially expressed exons and introns. The first custom track displays the fold-changes and the second
custom track displays the sequencing alignment of the three retained introns. We note that in this example, exons 8, 11 and 13, two intronic
sequences between exons 5 and 6, and one intronic sequence between exons 9 and 10, are over-expressed in the 4T1 sample.
doi:10.1371/journal.pone.0011981.g001
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also a tumor suppressor gene. It has been shown that the silencing
of prohibitin function increases tumor cell cycle progression in
prostate cancer [25]. PHB protein decreases colony formation of
T47D breast cancer cells by repressing E2F, a complex of growth
regulatory proteins [26]. Moreover, mutations in PHB gene have
been associated with sporadic breast cancer [27].
Finally, we found that within MAPK14, preferential retention of
intron 2 occurred specifically in 4T07-derived mammary tumors.
MAPK14-intron 2 retention shifts the reading frame and disrupts
a kinase domain in the protein product. MAPK14 is a member of
the MAPK complex whose controlled regulation plays a part in
cell proliferation and differentiation, whereas uncontrolled activa-
tion can lead to oncogenesis [28].
Strikingly, we also observed some novel transcript isoforms that
were not previously annotated. Representative examples are
MED24 and SRRT which were subsequently confirmed by
qRT-PCR (see below). Our exon array data showed an alternative
start of MED24 with the last seven exons of the transcript
predominantly expressed in 4T1-derived tumors (Figure 1A). The
wild-type MED24, expressed in all our samples, encodes a subunit
of the mediator complex TRAP, a transcriptional coactivator
complex necessary for the expression of almost all genes. The
truncated isoform found in 4T1-derived tumors could potentially
create a protein with deleterious activities. Additionally, an
intronic sequence in SRRT located between exons 5 and 6 was
differentially expressed between tumor samples. This intron
showed a strong over-expression in 168FARN and 4T07 cells
when comparing to 4T1 mammary tumor cells. SRRT, also
known as ARS2, is important for miRNA biogenesis during
miRNA-mediated gene silencing in proliferating cells [29].
Non-coding genic regions are widely retained in breast
cancer metastasis
A large number of the differences we detected are represented
by non-core probe sets, which targeted intronic regions. We
determined that 277,346 of the 493,710 (56.2%) analyzed probe
sets were non-core and we decided to interrogate 189,460 intronic
regions.We note that 49,588 of these non-core probe sets satisfied
the expression filtering criteria, including 2037 which showed
expression variations between tumor samples and mapping to
1725 intronic regions. This proportion represents 18% of the total
statistically significant introns and exons obtained. Besides the
expression variations of known coding regions, cancer cells are
susceptible to express such predominantly non-coding regions
because of general misregulation of gene expression and splicing.
Therefore, the inclusion of non-core probe sets in our analysis was
relevant. This enabled us to enrich the novel ASE proportion,
mainly the intron retention/cryptic category. Remarkably, the
proportion of tumor-specific over-expressed introns (Figure 2)
showed that 4T1 mammary tumors, which represent the highest
metastatic potential, had the greatest degree of intron inclusion
(775 over-expressed intronic regions) followed by 4T07-derived
mammary tumors and finally 168FARN samples (671 and 408
over-expressed intronic regions, respectively). However, probe sets
outside of annotated transcripts (518,024 probe sets) were
excluded from our investigation. We note that some of these
excluded probe sets, representing about half of total probe sets on
the array, were differentially expressed between tumors. They may
form new genes or produce new isoform variants by elongating the
ends of known transcripts; however this was not investigated in our
analysis.
Ontology and pathway analyses of differentially spliced
and expressed transcripts: candidate genes are mainly
involved in cancer hallmarks and genetic disorders
pathways
To identify biological pathways and functions enriched in our
significant genes, we conducted gene ontology and pathway
analyses with the set of genes that presented whole-gene expression
changes and/or isoform differences between the tumor samples
using the Ingenuity Pathways Analysis (IPA version 6.0) software
package (Ingenuity Systems, Mountain View, CA). The IPA
software compares its knowledge base - made up of all annotated
Table 1. List of some alternatively expressed probe sets.
Gene name
1 PS
2 PS location
3 168FARN vs. 4T1 4T07 vs. 4T1 ASE
6 Evidence
7
P-value
4 FC
5 P-value FC
CD44 4534496 E13 3.14610
204 2.81 3.38610
204 2.64 CE Yes
4740112 E11 6.39610
204 2.77 6.39610
204 2.72 CE Yes
4461784 I (E9-E10) 1.94610
204 2.06 1.55610
203 1.46 CE No
5425762 E8 1.02610
205 1.50 2.42610
204 0.96 CE Yes
4423264 I (E5-E6) 3.61610
205 1.51 2.28610
203 0.82 II No
4622064 I (E5-E6) 9.18610
205 1.18 8.16610
203 0.52 II No
Itgb1 5044002 I (E9-E10) 2.00610
205 1.58 1.12610
203 0.89 II Yes
Slc25a29 4968317 39 UTR 9.56610
205 22.17 9.56610
205 22.15 39 UTR Yes
MAPK14 4487560 I (E2-E3) 1.47610
201 20.18 2.05610
204 20.79 II No
Msx1 4993066 39 UTR 2.81610
203 0.88 5.22610
204 1.19 39 UTR No
Srrt 5382632 I (E5-E6) 2.54610
205 21.12 7.90610
206 21.36 II No
MFi2 5508279 E13 1.25610
204 21.88 1.54610
206 23.37 CE No
I(Ex-Ey): Intron between exon x and exon y.
The gene name
1, the probe set ID
2 and the relative probe set location
3 in the gene are indicated. For each pairwise comparison, the T-test p-value
4 and the log2(fold-
change)
5 are given. The nature of the isoform change
6 is shown (CE: cassette exon, II: intronic sequence inclusion, 39 UTR: differential 39 UTR). An existing RefSeq, mRNA,
or EST supporting the event is also mentioned
7.
doi:10.1371/journal.pone.0011981.t001
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the application. For each biological function or disease assigned,
IPA uses the right-tailed Fisher’s exact test to calculate a p-value
determining the probability that the user dataset has more
molecules associated with the biological function or disease than
the reference set of molecules is due by random chance. Among
the 2623 differentially expressed and/or spliced genes, 1224 have
known molecular and cellular functions. This proportion includes
genes previously reported to be involved in human diseases. We
observed several differentially expressed and/or spliced genes that
are implicated in cellular growth and proliferation, cellular death,
tissue development, cell to cell signaling and interaction, cellular
movement pathways, as well as in genetic disorders and cancers
(Tables 2, 3). Some of the most interesting gene candidates in
pathway interactions are described in detail below.
The CD44 gene in normal biological conditions is involved in
regulation of cell adhesion, proliferation and migration. It has
been previously reported to present an inclusion of 10 internal
variable exons (from exons 6 to 15) in mammary tumorigenesis
[9]. CD44 is known to interact with MAPK1, a member of the Erk
(extracellular signal-regulated kinase) complex, and also to a
complex of collagen proteins (Figure 3). Collagens are the most
abundant proteins in the extracellular matrix where it plays an
essential function in the organization of cells. Many candidate
genes, including several 4T1-overexpressed collagen subunit
genes, interact with Erk which is a complex consisting of MAP
kinase proteins and playing a role in cell division, growth and
proliferation (Supplementary Figure S1). Erk phosphorylates many
cytoplasmic and nuclear substrates required for the transcription
of several genes to pass from the G1 stage to the S stage in the
cellular division process [30]. There is evidence that in breast
cancer, the inhibition of ERK enhances the anti-estrogenic
treatment [31].
Another interesting example is CDH1, a tumor suppressor gene
[32] from the cadherin superfamily that encodes an epithelial cell-
cell adhesion protein. CDH1 acts on NF-kb, F-Actin and Mapk
Figure 2. Proportions of tumor-specific over-expressed intronic regions. The tumor samples are plotted on the x-axis, and the number of
tumor-specific intron inclusion on the y-axis.
doi:10.1371/journal.pone.0011981.g002
Table 2. Top height over-represented biological functions
and diseases for genes with isoform variations or
whole-transcript expression differences.
Function or disease
1 # genes
2 P-value
3
Genetic disorder 567 5.45610
247
Cancer 611 5.51610
243
Cellular growth and proliferation 467 5.00610
233
Cellular death 423 1.90610
229
Tissue development 282 7.75610
228
Cell-to-cell signaling and interaction 239 1.05610
221
Cellular development 314 1.11610
220
Cellular movement 254 5.14610
220
The gene pathway analysis retrieved biological functions and/or diseases
1 that
were most significant to the candidate genes. For each function or disease, the
number of significant genes
2 involved is mentioned. The right-tailed Fischer’s
exact test p-value
3 associated with a biological function or disease determines
the likelihood that our set of significant genes has more molecules associated
with the biological function or disease than the reference set of molecules is
due by random chance. A gene could be involved in more than one function or
disease.
doi:10.1371/journal.pone.0011981.t002
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implicated in cell-cell interactions, development and cell move-
ment. This candidate gene encodes a protein that facilitates
calcium-dependent homophilic interactions at cell-cell contact sites
known as adherens junctions. Mutations in this gene are related to
tumor cell growth and invasion in gastric, thyroid, colorectal and
ovarian cancers [33,34,35]. The low expression level or the loss of
E-Cadherin function is thought to contribute to cancer progression
by increasing proliferation, invasion and metastasis [33,34]. In
4T1 tumor cells, CDH1 was highly expressed compared to
168FARN or 4T07 cells (Additional file 1). This finding conflicts
with the expected low CDH1-expression level in highly metastasis
tumor. Given that primary tumor cells require adhesion within the
vasculature to invade distant organs via the bloodstream
[36,37,38], we hypothese that E-Cadherin could support tumor
cell attachment to the vessel wall to spread to distant sites via the
blood flow which is the main route by which primary tumor cells
invade to distant sites. Besides CDH1, several other significant
genes (such as LGALS7, ZFAND5, LSP1, MAPK14 and HSF1)
interact with the NF-kB complex that is involved in autoimmune
response, inflammation, cell proliferation and cell death by
controlling the expression of genes implicated in these processes
[39]. The supplementary Figure S2 shows a sub pathway
highlighting some of these interactions. Misregulation of NF-kB
has been associated with cancer, autoimmune diseases and
inflammatory responses [40,41]. Hence, the gene pathway analysis
identified differentially spliced and/or expressed candidate genes
during breast cancer metastasis that may have biological and
pathological relevance.
However, there were many highly significant genes showing
novel isoforms in our data that were not previously associated with
cancer. Some examples are IFT172, ACSBG1, MED24, AGRN
and CPXM2. The MED24 (mediator complex subunit 24) gene
acts indirectly on VDR [42], a 4T1-upregulated gene in our data,
which functions to inhibit p38 activity – a known mediator of
tumor cell death in colon cancer [43]. Hence, the gene pathway
investigation identified genes of which the functional relevance to
pathologies is not currently known and that could potentially be
linked to the process of breast cancer metastasis.
qRT-PCR validation of selected candidate genes confirms
the predicted alternative splicing events
In order to verify the presence of alternative splicing events that
emerged from our analysis, we performed RT-PCR assays of ten
selected candidate ASEs in MED24, SLC39A14, MFI2, SRRT,
CD44, CLK1 and HNRNPH1, (see Additional files 1 and 2 for
expression patterns of candidates). We amplified the differentially
spliced regions in the various tumor samples by RT-PCR using
primers pairs flanking and/or inside these regions (Supplementary
Table S1). The expected PCR products were readily obtained for
all candidate ASEs except for the SLC39A14 ASE and the SRRT-
intron inclusion between exons 13 and 14. For these two cases, we
Table 3. Examples of significant genes, in the gene pathway, having important implications in normal biological processes and
cancer.
Gene symbol
(RefSeq ID)
1 Biological function
2 Expression pattern
3 pathological implication
4
CD44 (NM_009851) regulation of cell growth; cell adhesion;
cell-matrix adhesion; cell-cell adhesion
High inclusion of three
novel introns in 4T1.
Increases adhesion [23] and invasion [7] of breast cancer
cells. Decreases cell death and apoptosis of tumor cells
[24]. Increases cell death of normal cell [61]. Increase cell
migration [6], movement [62] and binding [8] of tumor cells.
High inclusion of exons
8, 10, 11 and 13 in 4T1
PHB (NM_008831) apoptosis, growth, proliferation, colony
formation, cell cycle progression, migration,
transmembrane potential, binding
Cassette exon: exon 4
over-expressed in 4T1
Negative regulator of cell proliferation and tumor
suppressor [25,26]
BTG1 (NM_007569) proliferation, apoptosis, differentiation,
growth
Differential 39 UTR:
the 39 UTR region
over-expressed in 4T1
Anti-proliferative gene that regulates cell growth and
differentiation [63]
ITGB1 (NM_010578) G1/S transition of mitotic cell cycle; cellular
defense response; cell adhesion; positive
regulation of cell proliferation; germ cell
migration;
Intron inclusion
between exons 9 and
10 in 4T1
Decreases cell death of tumor cells [64,65]. Increases
cell death of normal cells [66,67]. Increases migration [68],
cell adhesion [68] and cell binding [69] of tumor cells.
ANGPT2 (NM_007426) angiogenesis; signal transduction; multicellular
organismal development; cell differentiation
Alternative
termination in 4T1
Increases cell death of normal cells [70].
HPRT1 (NM_013556) purine nucleotide biosynthetic process;
nucleoside metabolic process; protein
homotetramerization
Cassette exon: exon
1 over-expressed in 168FARN
and 4T07
Increases cell death of normal cells [71].
CCNT2 (NM_028399) differentiation, apoptosis, proliferation Intron inclusion
between exons 6 and
7 in 168FARN and 4T07
Decreases apoptosis of tumor cells in colon cancer [72]
MAPK14 (NM_011951) protein amino acid phosphorylation; cell
motion; chemotaxis; response to stress;
cell surface receptor linked signal
transduction; protein kinase cascade;
Intron inclusion between
exons 2 and 3 in 4T07
Increases cell death of normal cell [73,74]. Increase
developmental process of tumor cells [75].
SLK (NM_009289) nucleotide-excision repair; protein amino
acid phosphorylation; apoptosis
Cassette exon: exon 13 highly
expressed in 4T1
Increases cell death of normal cells [76].
For each gene, the symbol and the RefSeq accession number
1, the biological function
2, the type of splicing event
3 and the pathological implication
4 are given
3.
doi:10.1371/journal.pone.0011981.t003
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the products, we performed quantitative real time RT-PCR using
tumor samples from 168FARN and 4T1 for six candidate ASEs
that displayed positive qualitative RT-PCR results: MED24
(alternative start from exon 20 in 4T1), CD44 (from 59 to 39
ends, first retained intron in 4T1), CD44 (intron inclusion between
exons 9 and 10 in 4T1) and SRRT (intron inclusion between
exons 5 and 6 and CLK1 - intron inclusion between exons 7 and 8
in 4T1). The RT-PCR results across samples for the differentially
spliced gene regions of MED24, CD44 and SRRT were in
agreement with the corresponding expression data from the exon
array (Supplementary Figures S3, S4, S5).
MED24: We quantified the amplification of four distinct
genomic regions within the MED24 gene to assess the alternative
start event. (1) To quantify the constitutive region of MED24
expressed in all three tumor samples (region from exons 1 to 19),
we designed a primer pair spanning the region from exon 16 to
exon 18. Since all the exons in the constitutive region were
Figure 3. A network of molecular interactions containing differentially spliced or expressed genes between breast cancer tumors of
varying metastatic phenotype. Over- or under- expressed genes in 4T1 compared to 168FARN and 4T07 are respectively indicated by a green or a
red color of the gene-product icon. The over- or under-expression rate is proportional to the color intensity. Genes that are not colored are those that
are not differentially expressed or spliced in our data. The top functions or diseases where the gene-product are involved are cancer, tissue
development, cell-to-cell signaling and interaction.
doi:10.1371/journal.pone.0011981.g003
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them can be extended to the rest of the region. The region covered
by this primer pair was amplified at roughly equal levels in both
samples 168FARN and 4T1 (Supplementary Figure S3-A); that
was expected since the exon array showed no expression variation
between samples for this region. (2) We amplified the region
spanning the breakpoint between the constitutive block and the
alternative block (region from exons 20 to 26) of the transcript
predominantly expressed in 4T1. The primers pair designed for
this purpose covered the region from exons 19 to 20. The
quantitative real time RT-PCR results showed that this region was
roughly amplified at the same level in both 4T1 and 168FARN
(Supplementary Figure S3-B) and therefore proved that there was
an expression continuity between the constitutive block and the
alternative in both 168FARN and 4T1. This observation led us to
conclude that the whole transcript of MED24 is expressed in both
168FARN and 4T1. (3) We set a pair of primers (from exon 21 to
exon 23) to measure the alternative region which was over-
expressed in 4T1. The quantitative real time RT-PCR clearly
confirmed that the alternative block is abundant in 4T1
comparatively to 168FARN (Supplementary Figure S3-C). (4)
We wanted to exclude the hypothesis that the over-expression of
the alternative block in 4T1 compared to 168FARN signified an
alternative end of the transcript in 168FARN by the lack of the
alternative block. We found in public sequence databases mRNA
evidence (Genebank id: AK020269) that supports an early end of
MED24 and fully maps to the constitutive block from our study.
Therefore, we quantified the region corresponding to the end of
this mRNA. We observed much product variance between and
within replicate samples (Supplementary Figure S3-D), suggestive
of very low expression of that region. Given that the results of this
amplification assay were not convincing and that additionally this
region had no probe coverage in the exon array, we had no
evidence for an alternative end of MED24. Moreover, an
alternative end in 168FARN would show a higher expression of
the constitutive block than the alternative block, but the exon
array showed that the constitutive block and the alternative block
are expressed at the same level in sample 168FARN (Figure 1A,
bottom panel). Altogether, the quantitative real time RT-PCR
results for MED24 reproduced the corresponding expression data
from the exon array and gave strong evidence that the whole
transcript was expressed in all the samples, but the alternative
block was enriched in 4T1 compared to 168FARN and 4T07 and
is expressed as an additional independent transcript, most likely
using a novel, unnanotated promoter.
CD44: We measured two of the three novel CD44 intron
inclusions in the quantitative real time RT-PCR experiment (the
first intron retained in 4T1 and the intron inclusion between exons
9 and 10 in 4T1). The qRT-PCR products obtained were
consistent with our prediction (Supplementary Figure S4).
Additionally, we successfully sequenced the RT-PCR products of
these three introns, mapped the sequence to the mouse genome
using BLAT [44], and displayed it in the UCSC Genome Browser
(Figure 1C). The novel identified intron inclusions do not overlap
any coding mRNA or EST sequences and public sequence
databases have extremely weak unspliced EST evidences showing
splicing events involving these regions, but no observation for the
introns themselves. Therefore they are novel splicing events and
elongate the list of the ten CD44 cancer-specific variable exons.
Discussion
In this work, we used a splicing-sensitive microarray technology
to investigate changes in pre-mRNA splicing that are associated to
the formation of macroscopic metastases. Thus we focussed on
tumor cells that could escape the primary site but fail to form
macroscopic metastases (4T07, 168FARN) and those that can
leave the primary site and form growing metastases (4T1). Using
several stringent statistical selection criteria and filtering steps on
probe sets (exons) and meta-probe sets (transcripts), we obtained a
confident set of 2623 candidate genes that undergo isoform or
whole gene expression variations specific to metastatic character-
istics. Due to the inherent difficulty of unambiguously interpreting
statistically significant expression changes in Exon Array data [45],
only 7.7% of gene variations were classified into the gene-
expression change or known splicing change categories. The
remaining changes (92.3%) were difficult to interpret and may
reflect the complexity of gene expression variation in cancer. For
example, a single isoform may arise from multiple ASEs, which
makes interpretation of the expression pattern of such a transcript
very difficult to interpret. Isoform differences occurring in cancer
cells are not always crystalline and explained by standard known
changes. Although the Exon Array is a powerful tool, some ASEs
may be missed or misinterpreted by Exon Array. For example, a
fundamental limitation of Exon Array, or any other approach to
measure gene expressions changes, is the reality that splicing
events can introduce aberrations in the transcript such as
premature stop codons. If these transcripts are degraded at a
high rate by the RNA surveillance mechanisms (nonsense-
mediated decay), their expression levels may be detectable only
partially or not at all since they are unstable in the cell. Hence, the
analysis presented here uncovers only a part of the transcriptional
and post-transcriptional aberrations that distinguish mammary
tumors of differing metastatic phenotype. As a first step to
understanding the biological significance of alternatively spliced
genes, we carried out a global gene pathway analysis. We found
that nearly half of the significant genes have previously been
reported to be involved in cellular functions for which deregula-
tions are related to cancer. We also identified strongly significant
genes that have not previously linked to pathogenesis. It is
tempting to speculate that these genes may represent novel
oncogenes or specific modifiers of breast cancer metastasis.
Importantly, we have validated some predicted ASEs by qRT-
PCR and a high validation rate (80%, eight validated events out of
ten) demonstrated the efficiency of the exon array and our data
mining approach to identify gene regions that are significantly
enriched in one tumor type relative to another.
Additionally we compared our outcome with a recent study
(Dutertre et al, 2010 [46]) that used tumors derived from the same
cell lines (168FARN, 4T07 and 4T1), with the addition of the non-
metastatic 67NR cell line, which forms primary tumors but fail to
form distant metastases. This study assayed the tumor RNA
expression profiles on the exon array platform to implement a
prognostic classifier for breast cancer clinical outcome based on
splicing variants in breast cancer metastasis. They obtained a total
of 679 differentially spliced genes, including 209 genes with at least
one annotated alternative exon. Importantly, 62 of these 209 genes
had significant evidence for alternative splicing in our study. Of
these, 20 showed at least one consistent ASE between the two
studies while the remaining had different predicted events (Table
S2). Some of the consistent genes have been previously described
to be strongly related to cancer. An example is BCL2L11 that
encodes a protein belonging to the BCL-2 family, which is
composed of several pro- or anti–apoptotic regulators [47].
BCL2L11, which plays a crucial role in apoptosis initiation, is
frequently mutated in various human tumors leading to the loss of
its function [48,49]. In both independent studies, the analyses
showed that intron 2 is differentially expressed between tumor
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protein product. Another common example is SPINT2, a protein
that is over-expressed in pancreatic cancer and participates in
tumor cell invasion and metastasis [50]. Both studies found
SPINT2-exon 4 differentially expressed, a part of a Kunitz/Bovine
pancreatic trypsin inhibitor domain in the protein. The confident
set of common candidate genes between the two independent
studies strongly suggests that they may have essential roles in
breast cancer metastasis.
We used the Dice similarity coefficient [51] to evaluate the
closeness of our results with those (209 genes) from Dutertre’s
study. We obtained a Dice coefficient of 0.044 (2662/209+2623) -
with measure ranges from 0 (2260/209+2623) to 0.148 (26209/
209+2623) in this case – indicating an overlap of 30% (0.044/
0.1486100) between the two outcomes. The estimation of
statistical significance revealed a significant overlap between the
two studies (One-tailed Chi-square test p-value=1.17610
22),
providing further evidence that many of the significant genes that
are common to both studies may be implicated in breast cancer
metastasis – as they were detected by independent groups, using
slightly different experimental approaches. It should be noted that
larger outcome size in our study, as compared to Dutertre’s study,
resulted from our additional profiling of non-annotated gene
regions that were not considered in Dutertre’s study and that
revealed several intronic regions which were differentially
expressed between tumors with different metastatic potential.
However the candidate genes shared by both studies but with
different predicted outcome led us to hypothesize that one of the
confounding factors that affect tumor behaviors across labs may be
the age, the volume, the growth rate of the primary tumors at the
time of removal, the experiment conditions, the genetic instability
of the cell lines, the injection site and the computational analysis
for data mining. These factors alone or combined could influence
the expression profile of gene.
In conclusion, the connection between breast cancer and gene
splicing alteration is becoming increasingly compelling based both
on prior published data and our present work. Our data suggests
that, during breast cancer metastasis, numerous genes display
expression variations and/or splicing defects whose encoded
protein products could disturb normal biological processes.
Compared to other approaches based on DNA microarrays that
interrogate single whole genes, studying the transcriptome at the
exon level provides an accurate detailed knowledge about the
variations occurring within the genes and this could lead to
improved and more specific diagnostics or therapies. Moreover,
we demonstrate that non-coding gene regions, which are not
normally expressed can be differentially incorporated into
transcripts within breast cancers of differing metastatic phenotype.
We also observe that the proportion of intron inclusion was higher
in breast cancer cells with the greatest metastatic potential. Thus,
we suggest that aggressively metastatic breast cancer cells are
prone to splicing misregulation of non-coding gene regions. By
establishing which genes actively participate during different stages
of metastasis, it is possible that metastasis-specific isoforms may
emerge as breast cancer biomarkers [52]. Indeed, identified novel
isoforms or known isoforms that are not currently implicated in
any disease can be investigated as novel therapeutic targets [53,54]
in mammary tumors. For instance, a therapeutic small interfering
RNA (siRNA) [55,56] approach can be used to specifically target
and silence a gene isoform that disrupts a normal biological
process critical to breast cancer. Further functional characteriza-
tions of gene regions alternatively spliced have the potential to
improve the understanding of the complicated biological processes
connecting isoform variations and the metastasis machinery.
Materials and Methods
Cell Culture
The 4T1 murine mammary carcinoma cell line was obtained
from the American Type Culture Collection. Non-metastatic
168FRNA and 4T07 were kindly provided by Dr. Fred Miller
(Barbara Ann Karmanos Cancer Institute, Detroit, MI). All cell
lines were grown in DMEM supplemented with 10% fetal bovine
serum, 10 mmol/L HEPES, 1 mmol/L sodium pyruvate, 1.5 g/L
sodium bicarbonate, penicillin/streptomycin, and fungizone.
Mammary gland injection
Female BALB/c mice (4–6 weeks) were purchased from Charles
River Laboratories. The mice were housed in facilities managed
by the McGill University Animal Resources Centre, and all animal
experiments were conducted under a McGill University–approved
Animal Use Protocol in accordance with guidelines established by
the Canadian Council on Animal Care. Four mice were injected
(1610
25 cells) with 168FARN, five mice with 4T07 and four mice
with 4T01. Tumor volumes were calculated using the following
formula: pLW
2/6, where L is the length and W is the width of the
tumor. Tumors were surgically removed, using a cautery unit,
once they reached a volume between 100 and 125 mm3. Tumor
tissues were frozen to avoid RNA degradation.
RNA extraction and microarray hybridization
Tumor tissues were disrupted in a specific buffer, homogenized,
and then RNA was purified using Rneasy Mini kit (Qiagen)
following the manufacturer’s instructions. RNA 6000 Nano Chips
with the Agilent 2100 Bioanalyser (Agilent) were subsequently
used, following the manufacturer’s instructions, to verify the RNA
quality, integrity and the lack of gDNA contamination. Tumors
were hybridized independently at the functional genomics facility
of McGill University and Genome Quebec Innovation Centre
(Montreal, Quebec, Canada). Biotin-labeled target for the
microarray experiment were prepared using 1mg of total RNA.
We subjected the RNA to a ribosomal RNA removal process with
the Ribo/Minus Human/Mouse Transcriptome Isolation kit
(Invitrogen). cDNA was synthesized using the GeneChipH WT
(Whole Transcript) Sense Target Labeling and Control Reagents
kit as described by the manufacturer (Affymetrix). Then, the sense
cDNA was fragmented by UDG (uracil DNA glycosylase) and
APE 1 (apurinic/apyrimidic endonuclease 1) and biotin-labeled
with TdT (terminal deoxynucleotidyl transferase) using the
GeneChipH WT Terminal labeling kit (Affymetrix, Santa Clara,
USA). Hybridization was performed using 5 micrograms of
biotinylated target, which was incubated with the GeneChipH
Mouse Exon 1.0 ST array (Affymetrix) at 45uC for 16–20 hours.
Subsequently to hybridization, non-specifically bound material
was removed by washing and detection of specifically bound target
was performed using the GeneChipH Hybridization, Wash and
Stain kit, and the GeneChipH Fluidics Station 450 (Affymetrix).
The arrays were scanned using the GeneChipH Scanner 3000 7G
(Affymetrix) and raw data was extracted from the scanned images
and analyzed with the Affymetrix Power Tools software package
(Affymetrix). The microarray data has been deposited in the Gene
Expression Omnibus Database (accession: GSE21994).
Data pre-processing and analysis
Signal estimation. Signal estimates were derived from the
CEL files of the 13 arrays. The Affymetrix Power Tools software
package (Affymetrix) was used to quantile normalize the probe
fluorescence intensities and to summarize the probe set (represent-
ing exon expression) and meta-probe set (representing gene
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model (PLIER [57]) for probe set and ITER-PLIER for meta-
probe set. Presence or absence of probe set expression was
determined by the Detection Above BackGround (DABG)
statistics. For the probe set-level analysis we used the full set of
probe sets from the Exon Array including core and non-core
probe sets.
Filtering signal data. The filtering steps and parameters
described in this paragraph come from the Affymetrix technical
note for the identification of ASE using the exon array [58]. One
outlier biological replicates from 4T07 which didn’t cluster with
the replicates within the tumor type it belonged to, was identified
and removed following the Principal Component Analysis (PCA).
In order to be considered as expressed and included in the analysis
each exon had to satisfy the following four criteria (Supplementary
Figure S6): (1) the exon is called as Present in at least 50% of the
sample replicates of at least one tumor type. An exon is called as
‘‘present’’ if its probe set DABG p-value is less than 0.05; (2) the
probe set must have a low cross-hybridization potential (equal to 1)
to discard false positives. The signal intensities of probe sets having
a high cross-hybridization potential may come from a different
gene sequence; (3) the probe set must have a gene-level normalized
intensity lower than 5 (very large gene-level normalized intensity
may also implicate cross-hybridization to other genomic se-
quences); (4) the probe set must have a gene-level normalized
intensity greater than 0.20 (very low gene-level normalized
intensity probe sets were removed to discard features that may
have non-linear signal response.) For each gene containing the
previously filtered exons, two filtering criteria were used: (1) the
gene had at least 50% of core exons called as ‘‘present’’ in at least
50% of sample replicates in at least two tumor types; (2) the ITER-
PLIER gene intensity is greater than a threshold of 30.
We performed two concurrent analyses: AS analysis with the
probe set intensities and AS analysis with the gene-level normal-
ized intensities. There is no optimal method to analyze isoform
level data, and the relative merits of each approach are described
in some detail by Bemmo et al. [45]. For each analysis, a one-way
ANOVA-test was done on probe set scores to retrieve probe sets
that have a statistically significant change of expression between
tumor groups. We selected probe sets having an ANOVA P-value
lower than the P-value threshold (6.36610
24 for probe set
intensity analysis and 7.10610
24 for SI analysis) established by
the Benjamini-Hochberg FDR (False discovery rate) correction
[59] at a 0.05 level. 168FARN and 4T07 were compared against
4T1 by pairwise Student’s t-tests on probe sets scores. Logarithmic
fold-changes were computed between groups (168FARN/4T1 and
4T07/4T1). The genes expression intensities of meta-probe sets
were analyzed by the same way as probe sets. The statistical
significance of a whole gene expression was determined by an
FDR P-value threshold of 8.46610
23 computed from Anova-test
P-values. Since the SI analysis performs best when a gene has a
large number of constitutive exons comparatively to alternative
exons, we restricted the SI analysis to genes whose overall gene
expression does not change. Fold-changes and P-values of exons
within each gene have been uploaded and visualized in the UCSC
Genome Browser environment.
The visualization enabled us to classify ASEs (Supplementary
Figure S7). We examined the exon expression fold-changes within
the gene: if the whole gene expression changed (P,8.46610
23),
we categorized it as a gene expression change and determined the
possibly additional ASEs within the gene. If the whole gene
expression didn’t change (P$8.46610
23), we looked at the exon-
level: if an exon expression within the gene changed
(P,6.36610
24 for probe set intensity analysis or P,7.10610
24
for SI analysis), we categorized the ASE. Subsequently, we
performed a gene pathway analysis of significant genes with the
Ingenuity Pathways Analysis (IPA) software, version 6.0 (Ingenuity
Systems, Mountain View, CA).
Validation of alternative splicing events by RT-PCR and
qRT-PCR
We used a different RNA batch of the same tumors for the PCR
experiments. Total RNA was treated with 4U of DNAase I
(Ambion) for 30 minutes to remove any remaining genomic DNA.
First strand complementary DNA was synthesized using random
hexamers (Invitrogen) and Superscript II reverse transcriptase
(Invitrogen). All the candidate probe sets were internal and
possessing flanking exons in known RefSeq and mRNA isoforms.
We designed locus specific primers within the adjacent flanking
exons for the RT-PCR reaction (supplementary Table S1) by
using the Primer3 v. 0.4.0 software [60]. For MED24 gene for
which we predicted an alternative start in 4T1, additional primer
pairs were designed to amplify products corresponding to the
adjacent probe sets and which were not statistically significant.
Approximately 20 ng of total cDNA was then amplified by PCR
using Hot Start Taq Polymerase (Qiagen, Mississauga, Canada)
with an activation step at 95uC (15 min) followed by 35 cycles at
95uC (30 s), 58uC (30 s) and 72uC (40 s) and a final extension step
at 72uC (5 min). Amplicons were visualized by electrophoresis on a
2.5% agarose gel.
We performed a quantitative real time PCR in 168FARN and
4T1 for the primers pairs for which the qualitative RT-PCR
product were positively conclusive. Real-time analysis was carried
out using Power SYBR Green PCR Mix (Applied Biosystems)
following the manufacturer’s instructions on an ABI 7900 HT
(Applied Biosystems) instrument. The reaction was set up in 10ul
final volume applying the following conditions: 8ng of total cDNA
and 0.32 uM of gene specific primers, and cycling, 95C (15min),
95C (20s), 58C (30s), 72C (45s) for 40 cycles. Relative quantifica-
tion of each amplicon was evaluated in RNA from the tumor
samples in biological duplicates each in technical triplicates. For
each amplicon, including the mouse GAPDH used as endogenous
control, a standard curve was established using dilution series of a
mix of cDNA samples with known total cDNA concentration in
order to determine if the amplification reactions had the same
PCR efficiency. The cycle threshold (Ct) values for each replicate
were transformed to relative concentration using the estimated
standard curve function (SDS 2.1, Applied Biosystems) and
normalized based on GAPDH real-time data from the same
samples to account for well-to-well variability. Furthermore, CD44
RT-PCR products for two intron inclusion events were purified
and cloned for sequencing.
Supporting Information
Figure S1 A network of molecular interactions containing
differentially spliced or expressed genes between breast cancer
tumors of varying metastatic phenotype. Over- or under-
expressed genes in 4T1 compared to 168FARN and 4T07-derived
breast cancers are indicated by a green or a red color of the gene-
product icon, respectively. The degree of over- or under-
expression is proportional to the color intensity. Genes that are
not colored are those that are not differentially expressed or
spliced in our data. The top biological functions/processes or
diseases where the gene-products are involved are cancer, cell
cycle and cell death.
Found at: doi:10.1371/journal.pone.0011981.s001 (0.15 MB
PDF)
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PLoS ONE | www.plosone.org 10 August 2010 | Volume 5 | Issue 8 | e11981Figure S2 A network of molecular interactions containing
differentially spliced or expressed genes between breast cancer
tumors of varying metastatic phenotype. Over- or under-
expressed genes in 4T1 compared to 168FARN and 4T07-derived
breast tumors are indicated by a green or a red color of the gene-
product icon, respectively. The degree of over- or under-
expression is proportional to the color intensity. Genes that are
not colored are those that are not differentially expressed or
spliced in our data. The top biological functions/processes or
diseases where the gene-products are involved are cancer, cell
morphology, cell-to-cell signaling and interaction.
Found at: doi:10.1371/journal.pone.0011981.s002 (0.18 MB
PDF)
Figure S3 Quantitative RT-PCR validation of MED24 alter-
native start. In each panel, tumor samples are plotted on the x-axis
and real time RT-PCR GAPDH-normalized quantities on the Y
axis. We plotted the real time RT-PCR quantities for (A) the
constitutive block (region from exons 1 to 19), (B) the region
spanning the break point between the constitutive block and the
alternative block (from exon 16 to exon 18), (C) the alternative block
(regionfromexons20to26) and (D) the end oftheconstitutive block
(region from exons 21 to 23). We evaluated each tumor sample in
two biological replicates each ran in three technical replicates.
Found at: doi:10.1371/journal.pone.0011981.s003 (0.21 MB
PDF)
Figure S4 Quantitative RT-PCR validation of CD44 4T1-intron
retentions. In each panel, tumor samples are plotted on the x-axis
and real time RT-PCR GAPDH-normalized quantities on the Y
axis. We plotted the real time RT-PCR quantities for the first
retained intron between exons 5 and 6 (A) and the intron inclusion
between exons 9 and 10 (B). We evaluated each tumor sample in
two biological replicates, each ran in three technical replicates.
Found at: doi:10.1371/journal.pone.0011981.s004 (0.14 MB
PDF)
Figure S5 Quantitative RT-PCR validation of SRRT
168FARN-intron retention between exons 5 and 6. The tumor
samples are plotted on the x-axis and real time RT-PCR GAPDH-
normalized quantities on the Y axis. We conducted qRT-PCR in
two biological replicates (two independent tumors), each per-
formed in triplicate.
Found at: doi:10.1371/journal.pone.0011981.s005 (0.09 MB
PDF)
Figure S6 Workflow summary of the probe set and meta-probe
set signal filtering steps. Signal estimates were derived from the CEL
files. The probe logarithmic intensity error (PLIER) model was used
to summarize the probe set (representing exon expression)
intensities while the ITER-PLIER was used for meta-probe set
(representing gene expression) intensities. The Presence or absence
of probe set was determined by the Detection Above background
(DABG) p-value. In order to be considered as expressed and
included in the analysis each exon had to satisfy the following three
criteria: (1) expressed in at least one sample; (2) the cross-
hybridization potential equals to 1; (3) the gene-level normalized
intensity greater than 0.2 and lower than 5. For each gene
containing the previously filtered exons, two filtering criteria were
used: (1) the gene is expressed in at least two samples; (2) the gene
intensity is greater than a threshold of 30. We simultaneously
performed either a one-way ANOVA test on probe set intensities or
a one-way ANOVA test on meta-probe set intensities. Subsequent
to ANOVA tests, we applied a 0.05-level FDR (False discovery rate)
correction to determine the p-value threshold to identify significant
exons (P,6.36*10^24 for the probe set expression analysis;
P,7.10*10^24 for the SI analysis) and the significance of whole
gene expression (P,8.46*10^23: over-expressed in a sample).
Differentially expressed exons between paired samples were located
by performing pairwise T-test comparisons (168FARN and 4T07
against 4T1). The log2 transformed expression fold-changes (4T07/
4T1 and 168FARN/4T1) between paired sample comparisons
were also computed.
Found at: doi:10.1371/journal.pone.0011981.s006 (0.07 MB
PDF)
Figure S7 Workflow summary of the gene visualisation and the
manual curation for gene variation pattern classifications. The
probe set p-values and the probe sets fold-changes of T-test
pairwise comparisons are visualised in the context of gene
belongings to categorize transcripts variations.
Found at: doi:10.1371/journal.pone.0011981.s007 (0.06 MB
PDF)
Table S1 List of primers for validation. List of primers used in
the qualitative and quantitative RT-PCR validation. Probe sets in
blue are the target amplification probe sets whereas probe sets in
black are flanking probset spanned or containing the primers.
Found at: doi:10.1371/journal.pone.0011981.s008 (0.01 MB
PDF)
Table S2 Common significant differently expressed exons
between our study and Dutertre’s study. The gene symbol, the
gene name, the differentially spliced regions in our study and the
differentially spliced regions in Dutertre’s study are given. The
records highlighted in bold represent common genes with at least
one common predicted spliced regions.
Found at: doi:10.1371/journal.pone.0011981.s009 (0.03 MB
PDF)
File S1 UCSC browser links illustrating probe set level
expression differences (fold-change and p-values) for the top 143
isoforms differentially expressed between the samples, obtained
from the probe set level analysis.
Found at: doi:10.1371/journal.pone.0011981.s010 (0.15 MB
PDF)
File S2 UCSC browser links illustrating the probe set level
expression differences (fold-change and p-values) as well as the
normalized (SI) differences for the top 60 isoforms differentially
expressed between the samples, obtained from the Splicing Index
analysis.
Found at: doi:10.1371/journal.pone.0011981.s011 (0.10 MB
PDF)
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